Erratum: Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis (Kidney International (2006) 69, (1756-1764) DOI: 10.1038/sj.ki.5000336);Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis

Kidney International

Volumn 69, Issue 10, 2006, Pages 1756-1764

  Yang, H C ^a,b   Ma, L J ^a   Ma, J ^a,b   Fogo, A B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

Angiopoietin like protein 4; PAI 1; Podocytes; PPAR ; VEGF

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN LIKE PROTEIN 4; CYCLINE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PUROMYCIN AMINONUCLEOSIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN; WT1 PROTEIN;

ADOLESCENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; KIDNEY CORTEX; MACROPHAGE; MALE; MESANGIUM CELL; NEPHROTOXICITY; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

EID: 33646686362     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002025     Document Type: Erratum

References (36)

1. Shao D, Rangwala SM, Bailey ST et al. Interdomain communication regulating ligand binding by PPAR-gamma. Nature 1998; 396: 377-380.
2. Delerive P, Martin-Nizard F, Chinetti G et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999; 85: 394-402.
3. Kaplan F, Al-Majali K, Betteridge DJ. PPARs, insulin resistance and type 2 diabetes. J Cardiovasc Risk 2001; 8: 211-217.
4. Dubey RK, Zhang HY, Reddy SR et al. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol 1993; 265: R726-R732.
5. Ma LJ, Marcantoni C, Linton MF et al. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001; 59: 1899-1910.
6. Fogo AB. Animal models of FSGS: lessons for pathogenesis and treatment. Semin Nephrol 2003; 23: 161-171.
7. Kim YH GM, Kurnit D, Wharram B et al. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 2001; 60: 957-968.
8. Cuzzocrea S, Pisano B, Dugo L et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol 2004; 483: 79-93.
9. Imamoto E, Yoshida N, Uchiyama K et al. Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells. Biofactors 2004; 20: 37-47.
10. Sasaki M, Jordan P, Welbourne T et al. Troglitazone, a PPAR-gamma activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-alpha. BMC Physiol 2005; 5: 3-14.
11. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86.
12. Nakajima A, Wada K, Miki H et al. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 2001; 120: 460-469.
13. Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002; 34: 217-224.
14. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002; 283: F209-F220.
15. Kato K, Satoh H, Endo Y et al. Thiazolidinediones downregulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARgamma in endothelial function. Biochem Biophys Res Commun 1999; 258: 431-435.
16. Yuan Z, Liu Y, Liu Y et al. Cardioprotective effects of PPAR-γ activators in autoimmune myocarditis: anti-inflammatory actions associated with NF-κB blockade. Heart 2005; 91: 1203-1208.
17. Shimizu A, Kitamura H, Masuda Y et al. Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis. Am J Pathol 1997; 151: 1231-1239.
18. Ohashi R, Kitamura H, Yamanaka N. Peritubular capillary injury during the progression of experimental glomerulonephritis in rats. J Am Soc Nephrol 2000; 11: 47-56.
19. Kang DH, Anderson S, Kim YG et al. Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. Am J Kidney Dis 2001; 37: 601-611.
20. Fauconnet S, Lascombe I, Chabannes E et al. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator- activated receptors in bladder cancer cells. J Biol Chem 2002; 277: 23534-23543.
21. Yamakawa K, Hosoi M, Koyama H et al. Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun 2000; 271: 571-574.
22. Cho DH, Choi YJ, Jo SA et al. Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-independent signaling pathways. J Biol Chem 2004; 279: 2499-2506.
23. Yasuda E, Tokuda H, Ishisaki A et al. PPAR-gamma ligands upregulate basic fibroblast growth factor-induced VEGF release through amplifying SAPK/JNK activation in osteoblasts. Biochem Biophys Res Commun 2005; 328: 137-143.
24. Wang CH, Ciliberti N, Li SH et al. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation 2004; 109: 1392-1400.
25. Yoon JC, Chickering TW, Rosen ED et al. Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol Cell Biol 2000; 20: 5343-5349.
26. Kersten S, Mandard S, Tan NS et al. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem 2000; 275: 28488-28493.
27. Ito Y, Oike Y, Yasunaga K et al. Inhibition of angiogenesis and vascular leakiness by angiopoietin-related protein 4. Cancer Res 2003; 63: 6651-6657.
28. Ma LJ, Nakamura S, Aldigier JC et al. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 2005; 16: 966-976.
29. Schopfer FJ, Lin Y, Baker PR et al. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci USA 2005; 102: 2340-2345.
30. Sato M. Peroxisome proliferator activated receptor ligands and angiogenesis. Nippon Rinsho 2005; 63: 603-608.
31. Xin X, Yang S, Kowalski J et al. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999; 274: 9116-9121.
32. Wakino S, Kintscher U, Kim S et al. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1 → S transition in vascular smooth muscle cells. J Biol Chem 2000; 275: 22435-22441.
33. Yang FG, Zhang ZW, Xin DQ et al. Peroxisome proliferator-actived receptor-gamma ligand troglitazone induces apoptosis in renal cell carcinoma. Beijing Da Xue Xue Bao 2004; 36: 173-176.
34. Ishida H, Kato S, Nishimura M et al. Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats. Horm Metab Res 1998; 30: 673-678.
35. Ma LJ, Nakamura S, Whitsitt JS et al. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 2000; 58: 2425-2436.
36. Lai JP, Douglas SD, Wang YJ et al. Real-time reverse transcription-PCR quantitation of substance P receptor (NK-1R) mRNA. Clin Diagn Lab Immunol 2005; 12: 537-541.